Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

OBJECTIVE: To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s). RESEARCH DESIGN AND METHODS: A retrospective database analysis was performed of the Li...

Descripción completa

Detalles Bibliográficos
Autores principales: Best, Jennie H., Hoogwerf, Byron J., Herman, William H., Pelletier, Elise M., Smith, Daniel B., Wenten, Made, Hussein, Mohamed A.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005487/
https://www.ncbi.nlm.nih.gov/pubmed/20929995
http://dx.doi.org/10.2337/dc10-1393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005487/
https://www.ncbi.nlm.nih.gov/pubmed/20929995
http://dx.doi.org/10.2337/dc10-1393

Ejemplares similares